TP53 and cancer: To exploit the frequent presence of mutant p53 in tumors and target mutant p53 in cancer therapy, two strategies including restoration of wild-type p53 transcriptional activity and depletion of mutant p53 have been extensively undertaken, in addition to inhibition of downstream target pathways involved in mutant p53 GOF and induction of synthetic lethality to mutant p53.